What is Royalty Pharma's net change in cash?

Royalty Pharma (RPRX) reported net change in cash of -$32.3M in Q1 2026.

How has Royalty Pharma's net change in cash changed year-over-year?

Royalty Pharma's net change in cash decreased by 120.4% year-over-year, from $158.69M to -$32.3M.

What is the long-term trend for Royalty Pharma's net change in cash?

Over 2 years (2022 to 2025), Royalty Pharma's net change in cash has grown at a 35.2% compound annual growth rate (CAGR), from $169.7M to -$310.33M.

What does net change in cash mean?

Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Royalty Pharma RPRX Net Change in Cash

Net Change in Cash at other companies

Ligand PharmaceuticalsLGND

-$59.83M-146%

BridgeBio PharmaBBIO

$309.88M+321%

Rigel PharmaceuticalsRIGL

-$16.17M-47.5%

Roivant SciencesROIV

-$57.79M—

ALN

Alnylam PharmaceuticalsALNY

$53.61M0.0%

Ionis PharmaceuticalsIONS

-$198.88M-999%

Other financials

Income statement

See full

Revenue$630.6M+11.0%

Operating income$563.0M+5.4%

Net income$294.7M+23.1%

EPS (diluted)$0.67+21.8%

Balance sheet

See full

Cash & equivalents$586.4M-46.1%

Total debt$9.0B+17.8%

Total equity$9.9B+1.6%

Total assets$19.8B+12.5%

Cash flow

See full

Operating cash flow$718.2M+20.5%

Valuation

See full

Market cap$26.58B+69.3%

Enterprise value$34.97B+51.4%

P/E32.1×+16.8×

P/S10.9×+4.1×

Profitability

See full

Operating margin65.1%-18.9pp

Net margin33.9%-14.4pp

Returns & leverage

See full

Return on equity8.4%-2.7pp

Debt / equity0.9×+0.1×

Current ratio2.7×+1.1×

Where this comes from

Reported directly by Royalty Pharma in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: Royalty Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Royalty Pharma's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Royalty Pharma's net change in cash?: Royalty Pharma (RPRX) reported net change in cash of -$32.3M in Q1 2026.
How has Royalty Pharma's net change in cash changed year-over-year?: Royalty Pharma's net change in cash decreased by 120.4% year-over-year, from $158.69M to -$32.3M.
What is the long-term trend for Royalty Pharma's net change in cash?: Over 2 years (2022 to 2025), Royalty Pharma's net change in cash has grown at a 35.2% compound annual growth rate (CAGR), from $169.7M to -$310.33M.
What does net change in cash mean?: Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.